This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
“I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical...
New targeted therapies have extended survival, improved quality of life, and enabled more personalized treatment decisions based on genetic risk factors, age,...
CRA is a proud sponsor of the event for market access, reimbursement, and government policy experts. Ashley Fraser presents on “MFN – Implications in...
CRA is a proud sponsor of the event. Josh Sherman is a panelist during the session titled “Global antitrust trends reshaping the life sciences market”...
